We use rigorous data standards and patient-based forecasts to produce highly validated disease incidence and prevalence estimates across both developed and emerging countries. Combined with our disease teams’ industry-leading insight, market potential has never been so clear.
Age- and gender-specific population forecasts are applied across an expansive range of conditions within our disease coverage. Our team of experienced epidemiologists works hand-in-hand with our analyst teams across the globe, supporting the data with in-depth qualitative insights and context to help you identify the largest unmet needs and the biggest opportunities for expansion.
Robust sources and methodologies
Our epidemiological analyses utilize only the most relevant and representative studies, and are based on a clear, quantifiable methodology. We use the latest UN population data and validate our findings against both WHO and CDC estimates to provide a long-term view based on the gold-standard short-term data. Our coverage of indications incorporates both age- and gender-specific disease population estimates for the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK), in addition to 20-year forecasts.
As part of our commitment to provide best-in-class epidemiological analyses, we have assembled a team of highly trained epidemiologists who are strategically located in key pharma markets across the globe. Each of our specialists has a Master’s and/or Doctorate in epidemiology, biostatistics or a related field, ensuring that our analysis is as informed and authoritative as possible.
Context beyond projections
By discussing the factors that influence disease epidemiology and patient forecasts, our specialists can provide you with the context to understand how patient populations may change in the future. We offer detailed analysis of the prevalence or incidence for cases of diseases by country, year, age, gender, stage, and relevant subpopulation to provide a holistic view of a disease market.
With analyst teams situated across the globe, we are best placed to understand localized disease trends and use insights from local clinical opinion leaders to build sound strategic recommendations. We have extended our epidemiology coverage to cover pharmaceutical growth markets including China and India, offering an essential tool for those seeking further growth and expansion in these lucrative regions.